Pacira BioSciences Inc (PCRX)
17.77
+0.07
(+0.40%)
USD |
NASDAQ |
Nov 08, 11:07
Pacira BioSciences Revenue (TTM): 694.96M for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 694.96M |
| June 30, 2024 | 690.31M |
| March 31, 2024 | 681.75M |
| December 31, 2023 | 674.98M |
| September 30, 2023 | 665.69M |
| June 30, 2023 | 669.23M |
| March 31, 2023 | 669.17M |
| December 31, 2022 | 666.82M |
| September 30, 2022 | 654.06M |
| June 30, 2022 | 614.32M |
| March 31, 2022 | 580.50M |
| December 31, 2021 | 541.53M |
| September 30, 2021 | 513.31M |
| June 30, 2021 | 503.08M |
| March 31, 2021 | 442.99M |
| December 31, 2020 | 429.65M |
| September 30, 2020 | 421.10M |
| June 30, 2020 | 408.30M |
| March 31, 2020 | 435.40M |
| December 31, 2019 | 421.03M |
| September 30, 2019 | 393.72M |
| June 30, 2019 | 372.48M |
| March 31, 2019 | 353.98M |
| December 31, 2018 | 337.28M |
| September 30, 2018 | 321.24M |
| Date | Value |
|---|---|
| June 30, 2018 | 305.13M |
| March 31, 2018 | 291.95M |
| December 31, 2017 | 286.63M |
| September 30, 2017 | 280.45M |
| June 30, 2017 | 281.47M |
| March 31, 2017 | 280.18M |
| December 31, 2016 | 276.37M |
| September 30, 2016 | 272.79M |
| June 30, 2016 | 266.65M |
| March 31, 2016 | 256.16M |
| December 31, 2015 | 249.00M |
| September 30, 2015 | 241.47M |
| June 30, 2015 | 231.30M |
| March 31, 2015 | 219.32M |
| December 31, 2014 | 197.67M |
| September 30, 2014 | 169.44M |
| June 30, 2014 | 140.65M |
| March 31, 2014 | 110.63M |
| December 31, 2013 | 85.55M |
| September 30, 2013 | 62.44M |
| June 30, 2013 | 47.66M |
| March 31, 2013 | 42.87M |
| December 31, 2012 | 39.08M |
| September 30, 2012 | 32.87M |
| June 30, 2012 | 28.34M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
408.30M
Minimum
Jun 2020
694.96M
Maximum
Sep 2024
568.91M
Average
597.41M
Median
Revenue (TTM) Benchmarks
| Cyclo Therapeutics Inc | 1.132M |
| Revance Therapeutics Inc | 243.90M |
| NovaBay Pharmaceuticals Inc | 12.02M |
| Palatin Technologies Inc | -- |
| iBio Inc | -- |